Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection

Chest

Volumn 152, Issue 4, 2017, Pages 800-809

  Martiniano, Stacey L ^a,d   Wagner, Brandie D ^c   Levin, Adrah ^d   Nick, Jerry A ^d   Sagel, Scott D ^a   Daley, Charles L ^b,d  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Food Science and Human Nutrition   (United States)

^d DEPARTMENT OF MEDICINE   (United States)

Author keywords

clofazimine; cystic fibrosis; Mycobacterium abscessus; Mycobacterium avium; nontuberculous mycobacteria

Indexed keywords

AZITHROMYCIN; CLOFAZIMINE; MACROLIDE; MOXIFLOXACIN; VORICONAZOLE; ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANOREXIA; ANTIBIOTIC SENSITIVITY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRY SKIN; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM CHIMAERA; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM KANSASII; MYCOBACTERIUM MASSILIENSE; MYCOBACTERIUM SIMIAE; MYCOBACTERIUM YONGONENSE; NAUSEA; NEURALGIA; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT PROLONGATION; RETROSPECTIVE STUDY; SKIN ALLERGY; SKIN DISCOLORATION; STOMACH PAIN; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT WITHDRAWAL; VOMITING; ADOLESCENT; ATYPICAL MYCOBACTERIUM; CHILD; DOSE RESPONSE; FOLLOW UP; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PNEUMONIA; SPUTUM; THORAX RADIOGRAPHY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; CHILD; CLOFAZIMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; PNEUMONIA; RADIOGRAPHY, THORACIC; RETROSPECTIVE STUDIES; SPUTUM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85029757979     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2017.04.175     Document Type: Article

References (37)

1. Prevots, D.R., Marras, T.K., Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 36:1 (2015), 13–34.
2. Olivier, K.N., Weber, D.J., Wallace, R.J. Jr., et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 167:6 (2003), 828–834.
3. Qvist, T., Pressler, T., Hoiby, N., Katzenstein, T.L., Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis. Respir Res, 15, 2014, 41.
4. Floto, R.A., Olivier, K.N., Saiman, L., et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 71:suppl 1 (2016), i1–i22.
5. Griffith, D.E., Aksamit, T., Brown-Elliott, B.A., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175:4 (2007), 367–416.
6. Sexton, P., Harrison, A.C., Susceptibility to nontuberculous mycobacterial lung disease. Eur Respir J 31:6 (2008), 1322–1333.
7. Kim, R.D., Greenberg, D.E., Ehrmantraut, M.E., et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 178:10 (2008), 1066–1074.
8. O'Brien, R.J., Geiter, L.J., Snider, D.E. Jr., The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. Am Rev Respir Dis 135:5 (1987), 1007–1014.
9. Horsburgh, C.R. Jr., Selik, R.M., The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 139:1 (1989), 4–7.
10. Horsburgh, C.R. Jr., Caldwell, M.B., Simonds, R.J., Epidemiology of disseminated nontuberculous mycobacterial disease in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 12:3 (1993), 219–222.
11. Martiniano, S.L., Sontag, M.K., Daley, C.L., Nick, J.A., Sagel, S.D., Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thorac Soc 11:1 (2014), 36–44.
12. Kobashi, Y., Matsushima, T., Oka, M., A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 101:1 (2007), 130–138.
13. Jarand, J., Levin, A., Zhang, L., Huitt, G., Mitchell, J.D., Daley, C.L., Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 52:5 (2011), 565–571.
14. Koh, W.J., Jeon, K., Lee, N.Y., Kim, B.J., Kook, Y.H., Lee, S.H., et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 183:3 (2011), 405–410.
15. Cholo, M.C., Steel, H.C., Fourie, P.B., Germishuizen, W.A., Anderson, R., Clofazimine: current status and future prospects. J Antimicrob Chemother 67:2 (2012), 290–298.
16. Shen, G.H., Wu, B.D., Hu, S.T., Lin, C.F., Wu, K.M., Chen, J.H., High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 35:4 (2010), 400–404.
17. Garrelts, J.C., Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. DICP 25:5 (1991), 525–531.
18. Singh, H., Nel, B., Dey, V., Tiwari, P., Dulhani, N., Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur). Lepr Rev 82:1 (2011), 17–24.
19. Tang, S., Yao, L., Hao, X., et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 60:9 (2015), 1361–1367.
20. Hwang, T.J., Dotsenko, S., Jafarov, A., et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open, 4(1), 2014, e004143.
21. Field, S.K., Cowie, R.L., Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 124:4 (2003), 1482–1486.
22. Arbiser, J.L., Moschella, S.L., Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol 32:2 pt 1 (1995), 241–247.
23. Jarand, J., Davis, J.P., Cowie, R.L., Field, S.K., Fisher, D.A., Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and/or rifampin. Chest 149:5 (2016), 1285–1293.
24. Cariello, P.F., Kwak, E.J., Abdel-Massih, R.C., Silveira, F.P., Safety and tolerability of clofazimine as salvage therapy for atypical mycobacterial infection in solid organ transplant recipients. Transpl Infect Dis 17:1 (2015), 111–118.
25. Masur, H., Tuazon, C., Gill, V., et al. Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. J Infect Dis 155:1 (1987), 127–129.
26. Dautzenberg, B., Truffot, C., Mignon, A., et al. Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d'Etude et de Traitement des Infections a Mycobacteries Resistantes. Tubercle 72:3 (1991), 168–175.
27. Chaisson, R.E., Keiser, P., Pierce, M., et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 11:3 (1997), 311–317.
28. The Uppsala Monitoring Centre. The use of the WHO–UMC system for standardised case causality assessment. https://www.who-umc.org/media/2768/standardised-case-causality-assessment.pdf. Accessed March 8, 2017.
29. Roussel, G., Igual, J., Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections a Mycobacteries. Int J Tuberc Lung Dis 2:6 (1998), 462–470.
30. Kim, E.Y., Chi, S.Y., Oh, I.J., et al. Treatment outcome of combination therapy including clarithromycin for Mycobacterium avium complex pulmonary disease. Korean J Intern Med 26:1 (2011), 54–59.
31. Poole, G., Stradling, P., Worlledge, S., Potentially serious side effects of high-dose twice-weekly rifampicin. Br Med J 3:5770 (1971), 343–347.
32. Wallace, R.J. Jr., Brown-Elliott, B.A., McNulty, S., et al. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest 146:2 (2014), 276–282.
33. Tadolini, M., Lingtsang, R.D., Tiberi, S., et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur Respir J 48:3 (2016), 935–938.
34. Singh, S., Bouzinbi, N., Chaturvedi, V., Godreuil, S., Kremer, L., In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex. Clin Microbiol Infect 20:12 (2014), O1124–O1127.
35. Cowman, S., Burns, K., Benson, S., Wilson, R., Loebinger, M.R., The antimicrobial susceptibility of non-tuberculous mycobacteria. J Infect 72:3 (2016), 324–331.
36. Kobashi, Y., Matsushima, T., The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan-including a follow-up study. Respiration 74:4 (2007), 394–400.
37. van Ingen, J., Totten, S.E., Helstrom, N.K., Heifets, L.B., Boeree, M.J., Daley, C.L., In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother 56:12 (2012), 6324–6327.